Merck, Inc.
🇵🇭Philippines
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
Completed
- Conditions
- Crohn's DiseaseSpondylitis, AnkylosingPsoriasisArthritis, RheumatoidArthritis, Psoriatic
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2015-12-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4485
- Registration Number
- NCT00727298
Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Peginterferon alfa-2b (SCH 54031)Drug: Ribavirin (SCH 18908)
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1995
- Registration Number
- NCT00727259
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)
Terminated
- Conditions
- Hepatitis CHepatitis C, Chronic
- Interventions
- Biological: Peg-IFN alfa-2bDrug: Ribavirin
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 97
- Registration Number
- NCT00725842
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Pegylated interferon alfa-2b (PegIFN-2b)Drug: Ribavirin
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 353
- Registration Number
- NCT00725751
Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2430
- Registration Number
- NCT00724893
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 348
- Registration Number
- NCT00724958
Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT00725452
Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)
Phase 3
Completed
- Conditions
- Anesthesia, General
- Interventions
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 140
- Registration Number
- NCT00724932
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 64
- Registration Number
- NCT00725010
Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)
Completed
- Conditions
- Arthritis, Psoriatic
- Interventions
- Biological: Remicade (Infliximab)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 178
- Registration Number
- NCT00725296
© Copyright 2025. All Rights Reserved by MedPath